目的 探讨白介素-16(IL-16)在儿童哮喘中的发病机制,观察匹多莫德在儿童哮喘防治中的疗效.方法 将90例哮喘患儿随机分为治疗组55例,对照组35例;对照组予哮喘常规治疗,治疗组予常规治疗外,加用匹多莫德治疗2个月.治疗后随访观察12个月,治疗前后均监测IL-16、免疫球蛋白及淋巴细胞亚群.结果 与对照组比较,治疗组急性期病程天数、上下呼吸道感染次数、哮喘发作次数均少于对照组,差异均有统计学意义.哮喘急性发作期CD3+、CD4+、CD4+/CD8+淋巴细胞亚群较哮喘缓解期显著下降,免疫球蛋白轻度降低,IL-16较哮喘缓解期明显增高.匹多莫德治疗后3项指标均有明显改善.除IgG、IgM外,余均有统计学意义(P ＜ 0.05).结论 IL-16参与了哮喘发病的全过程,匹多莫德可下调IL-16的产生,从抗炎和提高免疫力的角度达到治疗哮喘的作用,安全有效.%Objective To explore IL-16 in the pathogenesis of childhood asthma. To evaluate the efficacy of Pidotimod in treatment of asthma. Methods Ninety patients with asthma were randomly divided into two groups,observation group (n = 55) and control group (n = 35). All patients of both groups had been given routine treatment,while patients of observation group were additionally treated with pidotimod for 2 months. Plasma level of IL-16,immunoglobulin, T cell subsets were determined by ELISA or flow cytometry before and after pidotimod treatment. All cases were followed up for one year. Results Days of recovering from acute asthmatic episodes, frequency of upper and low respiratory tract infection, frequenc y of asthma attack were lower in observation group than that of control group with statistical difference. During acute phase of asthma, level of CD3+、 CD4+、 CD4+/CD8+ were significantly reduced and level of IL-16 were significantly increased than that during relief phase, while pidotimod treatment can improve the immunological condition. Conclusions Pidotimod can safely and effectively lower the level of IL-6 in asthmatic children, by which may be the way for it to exert its therapeutic effeet
展开▼
